DeepMed Research

Chinese Academy of Medical Sciences

🇨🇳China

Country: 🇨🇳China

Ownership: Private, Subsidiary

Established: 2004-07-08

Employees: -

Market Cap: -

Website: http://www.pinganzhengxing.com

Clinical Trials

HGWD Improve the Paclitaxel-related Neurotoxicity in Patients With BC

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Huangqi Guizhi Wuwu decoction (HGWD) infusion packs

First Posted Date: 2022-10-04

Last Posted Date: 2022-10-04

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 92

Registration Number: NCT05566457

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

Phase 2

Recruiting

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Eribulin Mesylate
Drug: Lobaplatin

First Posted Date: 2022-09-19

Last Posted Date: 2022-09-19

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 40

Registration Number: NCT05546255

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

Low-dose Radiotherapy in iNHL

Phase 2

Recruiting

Conditions: Low-dose Radiotherapy
Indolent Lymphoma

Interventions: Radiation: Low-dose radiotherapy

First Posted Date: 2022-09-16

Last Posted Date: 2022-09-16

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 73

Registration Number: NCT05543070

Locations: 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC

Phase 2

Not yet recruiting

Conditions: Metastatic Esophageal Squamous Cell Carcinoma
Locally Advanced Esophageal Squamous Cell Carcinoma
Unresectable Esophageal Squamous Cell Carcinoma

Interventions: Drug: AK104
Drug: Cisplatin
Drug: Paclitaxel

First Posted Date: 2022-08-31

Last Posted Date: 2022-08-31

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 80

Registration Number: NCT05522894

Adjuvant Radiotherapy for pT1b Esophageal Cancer After Submucosal Endoscopic Resection

Completed

Conditions: Esophageal Cancer

First Posted Date: 2022-08-12

Last Posted Date: 2022-08-12

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 159

Registration Number: NCT05499195

Locations: 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy of ScTIL Injection (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Advanced Malignant Solid Tumors

Phase 1

Conditions: Advanced Tumor of Digestive Tract or Urinary System

Interventions: Biological: ScTIL injection

First Posted Date: 2022-08-12

Last Posted Date: 2022-08-12

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 48

Registration Number: NCT05499715

Locations: 🇨🇳
Cancer Hospital & Institute, Chinese Academy of Medical Sciences, Beijing, China

The Clinical Effect of Adaptive Posture-balance Cardiac Rehabilitation Exercise on Cardiovascular Diseases

Not Applicable

Completed

Conditions: Exercise Therapy
Balance Exercises
Cardiac Rehabilitation
Cardiovascular Diseases

Interventions: Behavioral: Adaptive posture-balance cardiac rehabilitation exercise

First Posted Date: 2022-08-11

Last Posted Date: 2022-08-11

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 100

Registration Number: NCT05496153

Locations: 🇨🇳
Tianjin Chest Hospital, Tianjin, Tianjin, China

Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer

Phase 2

Not yet recruiting

Conditions: Rectal Neoplasms Malignant
Radiotherapy

Interventions: Drug: Sintilimab
Radiation: Short-course radiotherapy
Combination Product: CAPOX/mFOLFOX

First Posted Date: 2022-08-02

Last Posted Date: 2022-08-02

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 588

Registration Number: NCT05484024

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, Beijing, China
🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China

Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 Resection

Conditions: Esophageal Cancer

Interventions: Radiation: Adjuvant Radiotherapy

First Posted Date: 2022-07-15

Last Posted Date: 2022-07-15

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 3591

Registration Number: NCT05460403

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Science, Beijing, Chaoyang, China

Construction and Validation of an Assessment Model of PCR After NAT on Breast Cancer Patients With AI Technology

Conditions: Breast Cancer

Interventions: Other: Neoadjuvant therapy

First Posted Date: 2022-07-01

Last Posted Date: 2022-07-01

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 1821

Registration Number: NCT05441098

Locations: 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy